Albumin-bound paclitaxel - Celgene Corporation

Drug Profile

Albumin-bound paclitaxel - Celgene Corporation

Alternative Names: ABI-007; ABRAXANE; Abraxane; ABRAXUS; Coraxane; Coroxane; Nab-Paclitaxel; Systemic nanoparticle albumin-bound paclitaxel

Latest Information Update: 05 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Abraxis BioScience
  • Developer Abraxis BioScience; AstraZeneca; Australian and New Zealand Urogenital and Prostate Cancer Group; Big Ten Cancer Research Consortium; Biotoscana; Cambridge University Hospitals; Cancer Research UK; Celgene Corporation; Columbia University; Eli Lilly; Emory University; Fondazione Sandro Pitigliani; Genentech; Institut fuer Frauengesundheit; M. D. Anderson Cancer Center; Mayo Clinic; Merck Sharp & Dohme; NCIC Clinical Trials Group; New York University School of Medicine; Oncosur; PrECOG; Southeastern Gynecologic Oncology; Taiho Pharmaceutical; University of California, Davis; University of Iowa; University of Texas M. D. Anderson Cancer Center; Washington University School of Medicine
  • Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma; Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase II Biliary cancer; Cholangiocarcinoma; Colorectal cancer; Head and neck cancer; Malignant melanoma; Small cell lung cancer; Urogenital cancer
  • Phase I/II Multiple myeloma; Solid tumours
  • No development reported Bladder cancer; Ovarian cancer; Prostate cancer
  • Discontinued Coronary artery restenosis; Peripheral arterial disorders; Vascular restenosis

Most Recent Events

  • 22 Oct 2018 Efficacy and safety data from the phase III IMpower130 trial in metastatic non-squamous non-small cell lung cancer (NSCLC) released by Genentech
  • 20 Oct 2018 Interim efficacy and adverse events data from the phase III IMpassion130 trial in Breast cancer released by Genentech
  • 26 Sep 2018 Phase-II clinical trials in Cholangiocarcinoma (Neoadjuvant therapy, Combination therapy) in USA (IV) (NCT03579771)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top